Imunon, Inc. Common Stock (IMNN) Stock Price

IMNNStock

$1.66−75.54%52W

Market Cap$9.31M

P/E—

PEG Ratio5.03

Div yield—

Beta2.02

IMNN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-61.87%

Price vs S&P 500 (4W)0.87%

PEG Ratio5.03

VGM Score39.70

Book Value / Share (Quarterly)$0.86

P/TBV (Annual)0.34x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-3.84

Price vs S&P 500 (YTD)-70.23%

Gross Margin (TTM)34.14%

Net Profit Margin (TTM)-6901.92%

EPS (TTM)$-5.74

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-5.74

EPS (Annual)$-1.58

ROI (Annual)-447.66%

Gross Margin (Annual)16.33%

Net Profit Margin (5Y Avg)-4275.20%

Cash / Share (Quarterly)$1.22

ROA (Last FY)-195.53%

EBITD / Share (TTM)$-4.85

ROE (5Y Avg)-173.69%

Operating Margin (TTM)-7361.54%

Cash Flow / Share (Annual)$-4.15

P/B Ratio2.62x

P/B Ratio (Quarterly)3.43x

Net Income / Employee (Annual)$-950,000

EV / Revenue (TTM)7.72x

Net Interest Coverage (TTM)-7.18x

ROA (TTM)-153.79%

EPS Incl Extra (Annual)$-1.58

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)1.15x

3-Month Avg Trading Volume0.10M

52-Week Price Return-75.54%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$3.94

P/S Ratio (Annual)17.62x

Asset Turnover (Annual)0.01x

52-Week High$6.96

Operating Margin (5Y Avg)-5140.80%

EPS Excl Extra (Annual)$-1.58

CapEx CAGR (5Y)69.59%

Tangible BV CAGR (5Y)51.40%

26-Week Price Return-50.62%

Quick Ratio (Annual)1.90x

13-Week Price Return-26.05%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.59x

Enterprise Value$4.02M

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-29.83%

Revenue / Employee (Annual)$0

Inventory Turnover (Annual)1.35x

Pretax Margin (Annual)-7494.00%

Cash / Share (Annual)$2.57

3-Month Return Std Dev46.49%

Gross Margin (5Y Avg)33.75%

Net Income / Employee (TTM)$-732,100

ROE (Last FY)-447.66%

Net Interest Coverage (Annual)-4.65x

EPS Basic Excl Extra (Annual)$-1.58

P/FCF (TTM)1.46x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.74

Receivables Turnover (Annual)0.00x

ROI (TTM)-341.23%

P/S Ratio (TTM)16.94x

Pretax Margin (5Y Avg)-4956.80%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.94

Price vs S&P 500 (52W)-93.85%

Year-to-Date Return-58.27%

5-Day Price Return0.63%

EPS Normalized (Annual)$-1.58

ROA (5Y Avg)-90.30%

Net Profit Margin (Annual)-7180.00%

Month-to-Date Return0.00%

Cash Flow / Share (TTM)$-3.05

EBITD / Share (Annual)$-1.56

Operating Margin (Annual)-7658.00%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-163.88%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.74

P/TBV (Quarterly)0.34x

P/B Ratio (Annual)1.66x

Inventory Turnover (TTM)2.94x

Pretax Margin (TTM)-7203.85%

Book Value / Share (Annual)$2.07

Price vs S&P 500 (13W)-28.84%

Beta2.02x

P/FCF (Annual)3.90x

Revenue / Share (TTM)$0.00

ROE (TTM)-341.23%

52-Week Low$1.47

vGradeC

mGradeD

vgmGradeD

IMNN Earnings Surprise History

Q2 25-1.87est. -4.14

Q3 25-1.16est. -1.82

Q4 25-1.30est. -1.82

Q1 26-0.84est. -1.28

Q2 26-0.54est. -0.91

IMNN Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.10

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
IMNNImunon, Inc. Common Stock	C	—	D	$1.66
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Imunon, Inc. Common Stock

Imunon Inc is a clinical-stage biotechnology company developing a non-viral DNA platform to treat various human diseases by leveraging the body's natural immune mechanisms. Its lead program, IMNN-001, is a DNA-based immunotherapy for ovarian cancer that has completed Phase II clinical trials. The company is also advancing IMNN-101, a COVID-19 booster vaccine candidate, currently in first-in-human studies.